ABSTRACT
Parasitic infections, although common in tropical and subtropical regions, are prevalent
worldwide because of changing immigration patterns and in international travel. The
burden of worm infection is enormous and the intensity of infection is usually high
among the poor and in immunocompromised individuals. Pulmonary eosinophilia occurs
in almost all metazoan infections. In the Western world, the most common infections
are caused by Strongyloides , Ascaris , Toxocara , and Ancylostoma species. Most of the nematodes multiply within the human host and cause pulmonary
eosinophilia during larval migration through the lungs. Despite larval migration through
the lungs, there is usually no permanent lung damage. The result is an increased number
of eosinophils in the airways or lung parenchyma with or without peripheral eosinophilia.
Loffler's syndrome, visceral larva migrans, and tropical pulmonary eosinophilia are
the most common infections that cause pulmonary eosinophilia. The most serious parasitic
eosinophilic lung disease is tropical pulmonary eosinophilia, a disorder caused by
the filarial worms Wuchereria bancrofti and Brugia malayi, in which cases have typically been reported to masquerade acute or refractory bronchial
asthma. Increasing awareness, newer diagnostic techniques, preventative measures,
and antiparasitic drugs are important in reducing the worldwide morbidity and mortality
from parasitic helminths and protozoa. This review focuses on common and some uncommon
causes of pulmonary parasitic eosinophilia and their manifestations, diagnosis, and
management.
KEYWORDS
Eosinophilia - pulmonary - infection - parasite
REFERENCES
1
Rothenberg M E.
Eosinophilia.
N Engl J Med.
1998;
338
1592-1600
2
Gleich G J, Adolphson C R, Leiferman K M.
The biology of eosinophilic leukocyte.
Annu Rev Med.
1993;
44
85-101
3
Sanderson C J.
Interleukin-5, eosinophils, and disease.
Blood.
1992;
79
3101-3109
4
Mossman T R, Coffman R L.
Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional
properties.
Annu Rev Immunol.
1989;
7
145-173
5
Schmid-Grendelmeier P, Altznauer F, Fischer B et al..
Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.
J Immunol.
2002;
169
1021-1027
6
Resnick M B, Weller P F.
Mechanism of eosinophil recruitment.
Am J Respir Cell Mol Biol.
1993;
8
349-355
7
Elsner J, Kapp A.
The chemokines network in eosinophil activation.
Allergy Asthma Proc.
2001;
22
139-148
8
Tefferi A.
Blood eosinophilia: A new paradigm in disease classification, diagnosis, and treatment.
Mayo Clin Proc.
2005;
80
75-83
9
Capron M.
Eosinophils and parasites.
Ann Parasitol Hun Comp.
1991;
66(Suppl 1)
44-45
10 Weller P F. Parasitic pneumonias. In Pennington JE (Ed). Respiratory infections:
diagnosis and management (2nd ed.) New York; Raven Press 1994: 695-714
11
Zumla A I, James D J.
Immunologic aspects of tropical disease.
Clin Chest Med.
2002;
23
283-308
12
Allen J N.
Eosinophilic lung diseases.
Pul Crit Care Update.
2005;
18
1-8
13
Sarinas P SA, Chitkara R K.
Ascariasis and hookworm.
Semin Resp Infect.
1997;
12
130-137
14
Awan A, Fein A M. Arunabh .
Tropical lung diseases.
Pul Crit Care Update.
2004;
16
1-9
15
Rexroth G, Keller C.
Chronic course of eosinophilic pneumonia in infections with Ascaris lumbricoides.
.
Pneumologie.
1995;
49
77-83
16
Liu L X, Weller P F.
Antiparasitic drugs.
N Engl J Med.
1996;
334
1178-1183
17
Neva F A.
Biology and immunology of human strongyloidiasis.
J Infect Dis.
1986;
153
397-406
18 Salata R A.
Intestinal nematodes. Parasitic lung diseases . In Mahmoud AAF Lung biology in health and disease. New York; Marcel Dekker 1997:
89-108
19
Wehner J H, Kirsch C M.
Pulmonary manifestations of strongyloidiasis.
Semin Resp Infect.
1997;
12
122-129
20
Siddiqui A A, Berk S L.
Diagnosis of Strongyloides stercolaris infection.
Clin Infect Dis.
2001;
33
1040-1047
21
Ottesen E A, Nutman T B.
Tropical pulmonary eosinophilia.
Annu Rev Med.
1992;
43
417-422
22
Sakakibara A, Baba K, Niwa S et al..
Visceral larva migrans due to Ascaris summ which presented with eosinophilic pneumonia and multiple intrahepatic lesions with
severe eosinophil infiltration. Outbreak in a Japanese area other than Kyushu.
Intern Med.
2002;
41
574-579
23
Chitkara R K, Sarinas P SA.
Dirofilaria, visceral larva migrans, and tropical pulmonary eosinophilia.
Semin Resp Infect.
1997;
12
138-148
24
Ong R KC, Doyle R L.
Tropical pulmonary eosinophilia.
Chest.
1998;
113
1673-1679
25
Feldman G J, Parker H W.
Visceral larva migrans associated with hypereosinophilic syndrome and the onset of
asthma.
Ann Intern Med.
1992;
116
838-840
26
Ray D, Abel R, Selvaraj K G.
Epidemiology of pulmonary eosinophilia in rural South India. A prospective study,
1981-1986.
J Epidemiol Community Health.
1993;
47
469-474
27
Low G L.
An interesting case of eosinophilia.
Trans R Soc Trop Med Hyg.
1916;
9
77-81
28
Weingarten R J.
Tropical eosinophilia.
Lancet.
1943;
1
103-105
29
Donohugh D L.
Tropical eosinophilia. An etiologic inquiry.
N Engl J Med.
1969;
269
1357-1364
30 Jeffrey H C, Leach R M, Cowan G O. Atlas of medical helminthology and protozoology
(3rd Ed). New York; Churchill Livingstone 1991: 77
31
Udwadia F E.
Tropical eosinophilia. A review.
Respir Med.
1993;
87
17-21
32
Khoo F Y, Dhanraj T J.
The roentgenographic appearance of eosinophilic lung (tropical eosinophilia).
AJR Am J Roentgenol.
1960;
83
251-259
33
Nath G, Mohapatra T M, Sen P C.
Circulating immune complexes and complement levels in bancroftian filariasis.
Indian J Pathol Microbiol.
1991;
34
92-98
34
Ray D, Sri Krishna K.
Alpha1 antitrypsin in tropical pulmonary eosinophilia.
Chest.
1993;
104
487-492
35
Sharma S K, Pande J N, Khilnani G C, Verma K, Kham M.
Immunologic and pulmonary function abnormalities in tropical eosinophilia.
Indian J Med Res.
1995;
101
98-102
36
Narayanan K, Balakrishnan A, Miyamoto S.
NF-kappaB is essential for induction of proinflammatory cytokine genes by filarial
parasite sheath proteins.
Mol Immunol.
2000;
37
115-123
37
Lobos E, Ondo A, Ottesen E A, Nutman T B.
Biochemical and immunologic characterization of a major IgE-inducing filarial antigen
of Brugia malayi and implications for the pathogenesis of tropical pulmonary eosinophilia.
J Immunol.
1992;
149
3029-3034
38
Ottesen E A.
Efficacy of diethylcarbamazine in eradicating infection with lymphatic dwelling filariae
in humans.
Rev Infect Dis.
1985;
7
341-356
39
Neva F A, Ottesen E A.
Tropical (filarial) eosinophilia.
N Engl J Med.
1978;
298
1129-1131
40
Rom W N, Vijayan V K, Cornelius M J et al..
Persistent lower respiratory tract inflammation associated with interstitial lung
disease in patients with tropical pulmonary eosinophilia following conventional treatment
with diethylcarbamazine.
Am Rev Respir Dis.
1990;
142
1088-1092
41
Karnad D R, Meisheri Y V.
Mebendazole with levamisole in tropical pulmonary eosinophilia: an alternative in
diethylcarbamazine allergy.
Trop Doct.
1992;
22
136-137
42
Ottesen E A, Campbell W C.
Ivermectin in human medicine.
J Antimicrob Chemother.
1994;
34
195-203
43
Narayanan K, Krishnamoorthy B, Ezhilarasan R, Miyamoto S, Balkrishnan A.
Targeting apoptotic signaling pathway and pro-inflammatory cytokine expression as
therapeutic intervention in TPE induced lung damage.
Cell Biol Int.
2003;
27
375-382
44
Blair D, Xu Z B, Agatsuma T.
Paragonimiasis and the genus Paragonimus
.
Adv Parasitol.
1999;
42
113-222
45
Nakamura-Uchiyama F, Mukae H, Nawa Y.
Paragonimiasis: a Japanese perspective.
Clin Chest Med.
2002;
23
409-420
46
Miyazaki I, Habe S.
A newly recognized mode of human infection with lung flukes, Paragonimus westermani
.
J Parasitol.
1976;
62
646-648
47
Uchiyama F, Morimoto Y, Nawa Y.
Re-emergence of paragonimiasis in Kyushu, Japan.
Southeast Asian J Trop Med Public Health.
1999;
30
686-691
48
Yokogawa M, Oshima T, Suguro T.
Intradermal test for paragonimiasis.
Japanese J Parasitol.
1955;
4
32-37
49
Katamine D, Imai J, Iwamoto I.
Immunological study on paragonimiasis.
Tropical Medicine.
1968;
10
28-38
50
Tsuji M.
On the immunoelectrophoresis for helminthological researches.
Japanese J Parasitol.
1974;
23
335-345
51
Ikeda T, Oikawa Y, Owashi M, Nawa Y.
Parasite specific IgE and IgG levels in the serum and pleural effusion of Paragonimus westermani patients.
Am J Trop Med Hyg.
1992;
47
104-107
52
Waikagul J.
Sero-diagnosis of paragonimiasis by enzyme-linked immunosorbent assay and immunoelectrophoresis.
Southeast Asian J Trop Med Public Health.
1989;
20
243-251
53
Intapan P M, Maleewong W, Wongkham C, Morakote N, Cha W.
Monoclonal antibody capture enzyme-linked immunosorbent assay for immuno-diagnosis
of human paragonimiasis heterotremus.
Journal of Tropical Medicine and Parasitology.
1999;
22
41-45
54
Fu S, Xiao S H, Catto B A.
Clinical use of Praziquantel in China.
Parasitol Today.
1988;
4
312-325
55
Calvopina M, Guderian R H, Paredes W, Chico M, Cooper P J.
Treatment of human paragonimiasis with Triclabendazole: clinical tolerance and drug
efficacy.
Trans R Soc Trop Med Hyg.
1998;
92
566-569
56
Ripert C, Couprie B, Moyou R, Gaillard F, Appriou M, Tribouley-Duret J.
Therapeutic effects of Triclabendazole in patients with paragonimiasis in Cameroon:
a pilot study.
Trans R Soc Trop Med Hyg.
1992;
86
417
57 Mahmoud A AF, Abdel Wahab M F.
Schistosomiasis . In: Warren KS, Mahmoud AAF Tropical and geographical medicine (2nd ed.) New York;
McGraw-Hill 1990: 470-471
58
Freedman D O, Kozarsky P K, Weld L H.
The global emerging infections sentinel network of the international society of travel
medicine.
J Travel Med.
1999;
6
94-98
59
Schwartz E.
Pulmonary schistosomiasis.
Clin Chest Med.
2002;
23
433-443
60
Hiatt R A, Sotomayor Z R, Sanches G, Zambrana M, Knight W B.
Factors in the pathogenesis of acute Schistosomiasis mansoni
.
J Infect Dis.
1979;
139
659-666
61
Morris W, Knauer M.
Cardiopulmonary manifestations of schistosomiasis.
Semin Respir Infect.
1997;
12
159-170
62
Davidson B L, El-kassimi F, Uz-zaman A, Pillai D K.
The “lung shift” in treated schistosomiasis: bronchoalveolar evidence of eosinophilic
pneumonia.
Chest.
1986;
89
455-457
63
Cetron M S, Chitsulo L, Sullivan J J et al..
Schistosomiasis in Lake Malawi.
Lancet.
1996;
348
1274-1278
64 Saconato H, Atallah A. Interventions for treating Schistosomiasis mansoni (Cochrane Database Syst Rev). In: The Cochrane Library, vol. 3. Oxford; 2001
65
Shuhua X, Binggui S, Chollet J, Tanner M.
Tegumental alterations in juvenile S. hematobium harbored in hamsters following Artemether
treatment.
Parasitol Int.
2001;
50
175-183
66
Gottstein B, Reichen J.
Hydatid lung disease (echinococcosis/hydatidosis).
Clin Chest Med.
2002;
23
397-408
67
Liance M, Janin V, Bresson-Hadni S, Vuitton D A, Houin R, Piarroux R.
Immunodiagnosis of echinococcus infections: confirmatory testing and species differentiation
by a new commercial Western blot.
J Clin Microbiol.
2000;
38
3718-3721
68
Poretti D, Felleisen E, Grimm F et al..
Differential immunodiagnosis between cystic hydatid disease and other cross reactive
pathologies.
Am J Trop Med Hyg.
1999;
60
193-198
69
Ito A, Ma L, Schantz P M et al..
Differential serodiagnosis for cystic and alveolar echinococcosis using fractions
of echinococcus granulosus cyst fluid antigen (antigen B) and E. multilocularis Protoscolex (EM 18).
Am J Trop Med Hyg.
1999;
60
188-192
70
Ben-Ismail R, Rouger P, Carme B, Gentilini M, Salmon C.
Comparative automated assay of anti-P1 antibodies in acute hepatic distomiasis and
in hydatidosis.
Vox Sang.
1980;
38
156-168
71
Dar F K, Buhidma M A, Kidwai S A.
Hydatid false positive serological test results in malignancy.
BMJ.
1984;
288
1197
72
Ferragut G, Ljungstrom I, Nieto A.
Relevance of circulating antigen detection to follow up experimental and human cystic
hydatid infections.
Parasite Immunol.
1998;
20
541-549
73
Stefaniak J.
Fine needle aspiration biopsy in the differential diagnosis of the liver cystic echinococcosis.
Acta Trop.
1997;
67
107-111
74
Safioleas M, Miseakos E P, Dosios T, Manti C, Lambrou P, Skalkeas G.
Surgical treatment of for lung hydatid disease.
World J Surg.
1999;
23
1181-1185
75
Keshmiri M, Baharvahdat H, Fattahi S H et al..
A placebo controlled study of albendazole in the treatment of pulmonary echinococcosis.
Eur Respir J.
1999;
14
503-507
76
Cangiotti L, Giulini S M, Muiesan P, Begni A, Tiberio G.
Hydatid disease of the liver: Long term results of surgical treatment.
G. Chir (Paris).
1991;
12
501-504
77
Novick R J, Tchervenkov C I, Wilson J A, Munro D D, Mulder D S.
Surgery for thoracic hydatid disease: A North American experience.
Ann Thorac Surg.
1987;
43
681-686
78
Frider B, Larrieu E, Odriozola M.
Long term outcome of asymptomatic liver hydatidosis.
J Hepatol.
1999;
30
228-231
79
Cobo F, Yarnoz C, Sesma B et al..
Albendazole plus Praziquantel versus albendazole alone as a pre-operative treatment
in intra abdominal hydatidosis caused by Echinococcus granulosus
.
Trop Med Int Health.
1998;
3
462-466
80
Lyche K D, Jensen W A.
Pleuro-pulmonary amebiasis.
Semin Respir Infect.
1997;
12
106-112
Rajinder K ChitkaraM.B. M.D.
Division of Pulmonary and Critical Care Medicine (111P)
3801, Miranda Ave., Bldg. 100, F2-142, Palo Alto, CA 94304
Email: rkc@stanford.edu